Skip to main content
. 2020 Aug 3;9(9):3. doi: 10.1167/tvst.9.9.3

Table 1.

Demographic Data of Patients Included in the Study

Group 1 (NIH 0) Group 2 (NIH 1) Group 3 (NIH 2) Group 4 (NIH 3)
Characteristic n = 14 n = 9 n = 16 n = 10
oGVHD severity None Mild Moderate Severe
Age, yrs
 Mean ± SD 56.1 ± 9.6 48.4 ± 15.4 52.6 ± 14.0 52.6 ± 15.2
 Range 38–73 25–69 28–74 24–69
Female, n (%) 5 (36) 2 (22) 7 (44) 1 (10)
Primary diagnosis, n (%)
 NHL 0 (0) 1 (11) 4 (25) 1 (10)
 MM 2 (14) 0 (0) 0 (0) 2 (20)
 ALL 0 (0) 2 (22) 3 (19) 2 (20)
 AML 8 (57) 3 (33) 7 (44) 3 (30)
 MDS 2 (14) 0 (0) 2 (13) 0 (0)
 CML 1 (7) 0 (0) 0 (0) 1 (10)
 CLL 0 (0) 1 (11) 0 (0) 0 (0)
 Other 1 (7) 2 (22) 0 (0) 1 (10)
HCT source, n (%)
 PB 12 (86) 9 (100) 16 (100) 10 (100)
 BM 2 (14) 0 (0) 0 (0) 0 (0)
No. of HLA-mismatch, n (%)
 1 1 (7) 1 (11) 2 (13) 1 (10)
 2 0 (0) 1 (11) 2 (13) 0 (0)
Unrelated donor, n (%) 3 (21) 5 (56) 8 (50) 5 (50)
Time elapsed between AHCT and ocular exam (mo)
 Mean ± SD 82.7 ± 85.7 66.1 ± 50.8 88.9 ± 62.6 90.6 ± 68.7
 Range 2–265 20–170 16–206 27–199

No statistically significant differences were detected in age or time elapsed since AHCT between the groups.